Seller record · Telehealth service
Direct Meds
Fails 3 of 8 criteria. S3, pharmacy identification: Prepared by licensed compounding pharmacies, which may vary; none is named. 2 more criteria also fail; see the table below.
At a glance
Direct MedsTelehealth service
- Price
- Semaglutide from $249, tirzepatide $399 a month
- Sells
- compounded semaglutide (sublingual and injection), tirzepatide, NAD+, and 3 more
- FDA letters
- 1 on file
Partner link. The site earns a commission on care started through it. Funding
Visit Direct MedsSee all eight dispositionsTelehealth service. Passes 5 of 8 criteria. Recorded against Standard v1.1.
A telehealth service selling compounded semaglutide and tirzepatide. An FDA warning letter names the operating entity, and the seller continues to operate.
Dispositions
| Code | Criterion | Disposition | Where it appears |
|---|---|---|---|
| S1 | Prescriber requirement | PASS | Direct Meds' how it works page |
| S2 | Prescription gating | PASS | Direct Meds' semaglutide product page |
| S3 | Pharmacy identification | FAIL | Direct Meds' terms |
| S4 | Compounding disclosure | FAIL | Direct Meds' tirzepatide product page; Direct Meds' website |
| S5 | Analytical documentation | FAIL | Direct Meds' how it works page |
| S6 | Business address | PASS | Direct Meds' website |
| S7 | Price disclosure | PASS | Direct Meds' how it works page |
| S8 | Enforcement status | PASS | FDA's website; FDA warning letter 716822 |
Evidence, criterion by criterion
The evidence behind each disposition in the table above, where it appears, and its date. A row that was re-checked later states its own date.
Products shown on the seller's own pages at the recorded date: compounded semaglutide (sublingual and injection), tirzepatide, NAD+, sermorelin, glutathione, BPC-157.
Other sellers of the same products
Who sells semaglutideWho sells tirzepatideWho sells sermorelinWho sells NAD+Who sells glutathioneWho sells BPC-157
Enforcement documents on file: 1 warning letter
FDA warning letter 716822, issued September 2025, to the operating company of Direct Meds dba DirectMedsClaims on Direct Meds' website that compounded semaglutide and tirzepatide use the same active ingredients as the brand drugs imply equivalence to an approved product and are false or misleading.
A warning letter alleges violations and requests a response. It does not halt a business, and it does not remove a seller from this ledger. Every letter recorded here.
Partner link. The site earns a commission on care started through it. Funding.
Visit Direct MedsDispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.